An Israeli artificial intelligence startup that helps women with in-vitro fertilization (IVF) cycles will be implementing its technology across fertility clinics in Spain.
Fairtility’s CHLOE (Cultivating Life Through Optimal Embryos) technology uses AI to assess the viability of a woman’s embryos throughout her IVF cycle, a medical procedure in which the egg is fertilized outside of the body.
Now, the startup has been chosen by one of Europe’s largest assisted reproduction and healthcare providers, Next Fertility, to implement CHLOE in all seven of its Spanish clinics.
The clinics will specifically use the CHLOE EQ, an AI-powered workspace that helps IVF lab assistants and patients throughout the process, including producing automated annotations about egg development, assessing the fertilization progress and tracking embryo growth.
This process creates transparency throughout the IVF cycle, and helps patients in understanding the reproductive potential of their oocytes (the ovary cells that are able to turn into eggs).
Because all of Next Fertility’s clinics in the country will be implementing CHLOE, the technology will be able to automate data collection and analysis processes, and ultimately increase efficiency within every one.
Additionally, Fairtility says that the Next Fertility embryologists will be able to choose the best embryos for transfer to the uterus using its technology.
“Next Fertility is at the forefront of transforming reproductive care, serving as a leader to the market, not only in Spain, but globally,” said Eran Eshed, CEO and co-founder of Fairtility.
“We’ve invested the time developing our technology to ensure cohesive and efficient integration across the IVF labs’ systems. This is aligned with our efforts to bring transparency to the entire reproductive care journey,” he said.
“Transparency is essential for responsible AI development, especially when it intersects with human life.”